Dataset Preview
The full dataset viewer is not available (click to read why). Only showing a preview of the rows.
The dataset generation failed because of a cast error
Error code: DatasetGenerationCastError
Exception: DatasetGenerationCastError
Message: An error occurred while generating the dataset
All the data files must have the same columns, but at some point there are 20 missing columns ({'Enrollment', 'Study Documents', 'Start Date', 'Acronym', 'Secondary Outcome Measures', 'Phases', 'First Posted', 'Locations', 'Primary Outcome Measures', 'Sex', 'Primary Completion Date', 'Last Update Posted', 'Completion Date', 'Funder Type', 'Sponsor', 'Other Outcome Measures', 'Brief Summary', 'Age', 'Results First Posted', 'Collaborators'})
This happened while the csv dataset builder was generating data using
hf://datasets/pankajmathur/National_Library_of_Medicine_Studies_data/ctg-studies_500k.csv (at revision ac689bb79e0810b3b447253a481014b4ab33d037)
Please either edit the data files to have matching columns, or separate them into different configurations (see docs at https://hf.co/docs/hub/datasets-manual-configuration#multiple-configurations)
Traceback: Traceback (most recent call last):
File "/src/services/worker/.venv/lib/python3.9/site-packages/datasets/builder.py", line 2013, in _prepare_split_single
writer.write_table(table)
File "/src/services/worker/.venv/lib/python3.9/site-packages/datasets/arrow_writer.py", line 585, in write_table
pa_table = table_cast(pa_table, self._schema)
File "/src/services/worker/.venv/lib/python3.9/site-packages/datasets/table.py", line 2302, in table_cast
return cast_table_to_schema(table, schema)
File "/src/services/worker/.venv/lib/python3.9/site-packages/datasets/table.py", line 2256, in cast_table_to_schema
raise CastError(
datasets.table.CastError: Couldn't cast
NCT Number: string
Study Title: string
Study URL: string
Study Status: string
Study Results: string
Conditions: string
Interventions: string
Study Type: string
Study Design: string
-- schema metadata --
pandas: '{"index_columns": [{"kind": "range", "name": null, "start": 0, "' + 1363
to
{'NCT Number': Value(dtype='string', id=None), 'Study Title': Value(dtype='string', id=None), 'Study URL': Value(dtype='string', id=None), 'Acronym': Value(dtype='string', id=None), 'Study Status': Value(dtype='string', id=None), 'Brief Summary': Value(dtype='string', id=None), 'Study Results': Value(dtype='string', id=None), 'Conditions': Value(dtype='string', id=None), 'Interventions': Value(dtype='string', id=None), 'Primary Outcome Measures': Value(dtype='string', id=None), 'Secondary Outcome Measures': Value(dtype='string', id=None), 'Other Outcome Measures': Value(dtype='string', id=None), 'Sponsor': Value(dtype='string', id=None), 'Collaborators': Value(dtype='string', id=None), 'Sex': Value(dtype='string', id=None), 'Age': Value(dtype='string', id=None), 'Phases': Value(dtype='string', id=None), 'Enrollment': Value(dtype='int64', id=None), 'Funder Type': Value(dtype='string', id=None), 'Study Type': Value(dtype='string', id=None), 'Study Design': Value(dtype='string', id=None), 'Start Date': Value(dtype='string', id=None), 'Primary Completion Date': Value(dtype='string', id=None), 'Completion Date': Value(dtype='string', id=None), 'First Posted': Value(dtype='string', id=None), 'Results First Posted': Value(dtype='float64', id=None), 'Last Update Posted': Value(dtype='string', id=None), 'Locations': Value(dtype='string', id=None), 'Study Documents': Value(dtype='string', id=None)}
because column names don't match
During handling of the above exception, another exception occurred:
Traceback (most recent call last):
File "/src/services/worker/src/worker/job_runners/config/parquet_and_info.py", line 1396, in compute_config_parquet_and_info_response
parquet_operations = convert_to_parquet(builder)
File "/src/services/worker/src/worker/job_runners/config/parquet_and_info.py", line 1045, in convert_to_parquet
builder.download_and_prepare(
File "/src/services/worker/.venv/lib/python3.9/site-packages/datasets/builder.py", line 1029, in download_and_prepare
self._download_and_prepare(
File "/src/services/worker/.venv/lib/python3.9/site-packages/datasets/builder.py", line 1124, in _download_and_prepare
self._prepare_split(split_generator, **prepare_split_kwargs)
File "/src/services/worker/.venv/lib/python3.9/site-packages/datasets/builder.py", line 1884, in _prepare_split
for job_id, done, content in self._prepare_split_single(
File "/src/services/worker/.venv/lib/python3.9/site-packages/datasets/builder.py", line 2015, in _prepare_split_single
raise DatasetGenerationCastError.from_cast_error(
datasets.exceptions.DatasetGenerationCastError: An error occurred while generating the dataset
All the data files must have the same columns, but at some point there are 20 missing columns ({'Enrollment', 'Study Documents', 'Start Date', 'Acronym', 'Secondary Outcome Measures', 'Phases', 'First Posted', 'Locations', 'Primary Outcome Measures', 'Sex', 'Primary Completion Date', 'Last Update Posted', 'Completion Date', 'Funder Type', 'Sponsor', 'Other Outcome Measures', 'Brief Summary', 'Age', 'Results First Posted', 'Collaborators'})
This happened while the csv dataset builder was generating data using
hf://datasets/pankajmathur/National_Library_of_Medicine_Studies_data/ctg-studies_500k.csv (at revision ac689bb79e0810b3b447253a481014b4ab33d037)
Please either edit the data files to have matching columns, or separate them into different configurations (see docs at https://hf.co/docs/hub/datasets-manual-configuration#multiple-configurations)Need help to make the dataset viewer work? Make sure to review how to configure the dataset viewer, and open a discussion for direct support.
NCT Number string | Study Title string | Study URL string | Acronym string | Study Status string | Brief Summary string | Study Results string | Conditions string | Interventions string | Primary Outcome Measures string | Secondary Outcome Measures string | Other Outcome Measures string | Sponsor string | Collaborators string | Sex string | Age string | Phases null | Enrollment int64 | Funder Type string | Study Type string | Study Design string | Start Date string | Primary Completion Date string | Completion Date string | First Posted string | Results First Posted null | Last Update Posted string | Locations string | Study Documents null |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
NCT06585761 | Effect of Sodium Glucose Co-tansporter 2 Inhibitors (SGLT2I) on Inflammatory and Oxidative Stress Markers Level in Heart Failure Patients | https://clinicaltrials.gov/study/NCT06585761 | null | RECRUITING | The aim of this study is to explore the effect of SGLT2i on the levels of cardiac biomarkers, inflammatory and stress markers in Egyptian heart failure patients to provide a better understanding of mechanism that might assist in tailoring treatment strategies in patients with various forms of HF especially in Egyptian ... | NO | Heart Failure | null | measure effect of SGLT2I ON serum concentration ( level) of cardiac biomarkers in heart failure patients before and after the intervention, At follow up, patients will be clinically evaluated for the changes in serum levels of the studied biomarkers the studied biomarker is NT-proBNP, its concentration is measured in p... | measure effect of SGLT2I ON serum concentration ( level) of cardiac inflammatory marker ( IL-6) in heart failure patients before and after the intervention, At follow up, patients will be clinically evaluated for the changes in serum levels of the studied biomarker
Il-6 serum concentration is measured in pg/mL, 1 year... | measure effect of SGLT2I ON serum concentration( level) of cardiac stress markers in heart failure patients before and after the intervention, At follow up, patients will be clinically evaluated for the changes in serum levels of the studied biomarkers such as MDA which plasma concentration is measured in nM, 1 year | Kafrelsheikh University | null | ALL | ADULT, OLDER_ADULT | null | 60 | OTHER | OBSERVATIONAL | Observational Model: |Time Perspective: p | 2024-02-15 | 2025-06-30 | 2025-06-30 | 2024-09-05 | null | 2024-09-05 | null | null |
NCT06585748 | Lidocaine Spray Use on Patients Comfort in Undergoing Bladder Catheterization | https://clinicaltrials.gov/study/NCT06585748 | null | RECRUITING | Bladder catheterization is a procedure frequently performed in emergency departments and may cause symptoms such as pain and discomfort in patients. This study hypothesizes that lidocaine spray application will improve patient compliance and comfort from the outset and facilitate smoother medical procedures. In our pro... | NO | Urinary Catheterization As the Cause of Abnormal Reaction of Patient, or of Later Complication, Without Mention of Misadventure At Time of Procedure | null | Lidocaine and Pain, The FLACC scale assesses acute pain based on facial expression, leg position, activity, crying, and consolability Each category is scored from 0-2, with 0 indicating a calm patient and 10 indicating a visibly distressed patient ., 0., 15., 30., and 60. minutes | Lidocaine and comfort, Wong-Baker pain scale evaluates pain based solely on facial expressions. A score of 0 represents no pain, while a score of 10 represents unbearable pain ., 0., 15., 30., and 60. minutes | null | Ankara City Hospital Bilkent | null | MALE | ADULT, OLDER_ADULT | null | 100 | OTHER | OBSERVATIONAL | Observational Model: |Time Perspective: p | 2022-07-01 | 2023-07-01 | 2024-12-01 | 2024-09-05 | null | 2024-09-05 | null | null |
NCT06585735 | Proteolytic Enzyme Fortified Protein Supplement in Chronic Pancreatitis. | https://clinicaltrials.gov/study/NCT06585735 | null | NOT_YET_RECRUITING | A complex disease, Chronic Pancreatitis (CP) is caused by a wide range of factors, including smoking, alcoholism, autoimmune disorders, and obstruction of the major pancreatic duct. In patients who are genetically susceptible to the condition, these factors can result in damage to the acinar, ductal, and islet cells, a... | NO | Chronic Pancreatitis|Malnutrition | DIETARY_SUPPLEMENT: Proteolytic enzyme fortified protein supplement | Weight gain, Improvement in body weight at least by 10% of the original weight., 6 weeks | Improvement in body composition, Change in composition in medical body composition analyser (mBCA) test, 6 weeks|Improvement in body function 1, Muscle strength will be assessed by Jamar Hand grip Dynamometer at baseline and at the end of 6 weeks., 6 weeks|Improvement in body function 2, Muscle function will be assesse... | null | Asian Institute of Gastroenterology, India | null | ALL | ADULT, OLDER_ADULT | null | 60 | OTHER | INTERVENTIONAL | Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT | 2024-09-01 | 2025-03-31 | 2025-06-30 | 2024-09-05 | null | 2024-09-05 | Asian Institute of Gastroenterology Hospitals, Hyderabad, Telangana, 500032, India | null |
NCT06585722 | Association Between Venous Excess Ultrasound Grading System and Acute Kidney Injury in the ICU Population | https://clinicaltrials.gov/study/NCT06585722 | VExUS ICU | RECRUITING | Fluid resuscitation is one of the cornerstones of treatment in ICU patients. Nonetheless, excessive fluid administration can lead to fluid overload which has been associated with worse outcomes in the ICU. To prevent this, assessments of fluid responsiveness are commonly employed. However, fluid responsiveness does not... | NO | Fluid Overload|Kidney Injury|Make-30 | null | Rate of acute kidney injury, Clinically relevant acute kidney injury in the ICU: a 200% rise in creatinine or the use of renal replacement therapy, within 30 days of admission to the ICU|Mortality, death of all causes, within 30 days of admission to the ICU|Rate of MAKE-30, a composite endpoint of mortality and acute k... | null | Lung ultrasound score, a score for lung aeration as assessed by ultrasound ranging from 0 to 36 where 0 is the normal physiological state, maximum of 3 times during the first 7 days of admission|Cardiac function as assed by ultrasound, determined by eyeballing and measurement of the tricuspid annular plane systolic exc... | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | null | ALL | ADULT, OLDER_ADULT | null | 136 | OTHER | OBSERVATIONAL | Observational Model: |Time Perspective: p | 2023-02-01 | 2024-09-05 | 2024-09-05 | 2024-09-05 | null | 2024-09-05 | null | null |
NCT06585709 | OUD (Opioid Use Disorder) Target Trial | https://clinicaltrials.gov/study/NCT06585709 | null | NOT_YET_RECRUITING | In this research study the investigators will work with 80-participants with opioid use disorder who are starting treatment with the medication buprenorphine and are trying to quit using opioids.
The investigators are trying to learn two things:
1. Can an MRI brain marker be used to predict which participants will be... | NO | Opioid Use Disorder | DEVICE: Active repetitive Transcranial Magnetic Stimulation (rTMS)|DEVICE: Sham repetitive Transcranial Magnetic Stimulation (rTMS) | Number of participants with Relapse Free survival, The number of participants who have not met relapse criteria in the 12-week follow-up phase. Relapse is defined as a) any opioid use in 4 consecutive weeks, or b) any opioid use on 7 consecutive days., Up to 12 weeks | Number of participants with high ventral striatal reactivity using the Reassessment of Craving (ROC) task, Baseline|Number of participants with low ventral striatal reactivity using the Reassessment of Craving (ROC) task, Baseline | null | Duke University | Stanford University | ALL | ADULT, OLDER_ADULT | null | 80 | OTHER | INTERVENTIONAL | Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT | 2024-10-01 | 2026-07-31 | 2026-10-31 | 2024-09-05 | null | 2024-09-05 | Duke University, Durham, North Carolina, 27705, United States | null |
NCT06585696 | A Phase 3 Clinical Study to Evaluate the Efficacy and Safety of Botulinum Toxin Type A for Injection (CU-20101) | https://clinicaltrials.gov/study/NCT06585696 | null | RECRUITING | This is a Phase 3 clinical study to evaluate the efficacy, safety, and immunogenicity of single/repeated injections of CU-20101 in the treatment of moderate to severe glabellar lines. The study consisted of a 7-day screening period, Study Part 1 (randomized double-blind controlled study) and Period 2 (open-label study)... | NO | Moderate to Severe Glabellar Striae | DRUG: CU-20101 treatment for Moderate to Severe Glabellar Striae | • Proportion of subjects with an FWS score of 0 or 1 and both with a decrease of ≥ 2 points from baseline as assessed on-site by the investigator and the subject at Week 4 after the first round of injection., • Proportion of subjects with an FWS score of 0 or 1 and both with a decrease of ≥ 2 points from baseline as as... | null | null | Cutia Therapeutics（Wuxi）Co.,Ltd | null | ALL | ADULT, OLDER_ADULT | null | 554 | INDUSTRY | INTERVENTIONAL | Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT | 2024-06-11 | 2026-03-01 | 2026-05-01 | 2024-09-05 | null | 2024-09-05 | Peking University First Hospital, Beijing, Beijing, 200443, China | null |
NCT06585683 | Post-Trial Tuberculosis Case Finding: a Substudy of CoVPN 3008 (Ubuntu) | https://clinicaltrials.gov/study/NCT06585683 | CoVPN3008TB | NOT_YET_RECRUITING | This substudy aims to identify cases of tuberculosis after the Ubuntu clinical trial (CoVPN 3008) is completed. | NO | Tuberculosis | null | Proportion of participants with TB, The 95% confidence interval on the proportion of participants with TB will be estimated using the "score" method, Measured at Day 1, Day 4 and week 26|Association parameters of each demographic variable with confirmed TB., Proportions and 95% CIs will be estimated using the score met... | null | null | COVID-19 Prevention Network | null | ALL | ADULT, OLDER_ADULT | null | 6,000 | NETWORK | OBSERVATIONAL | Observational Model: |Time Perspective: p | 2024-09-12 | 2025-10-04 | 2025-10-05 | 2024-09-05 | null | 2024-09-05 | null | null |
NCT06585670 | Mindfulness Approach for Reducing Anxiety and Gloom in Ocular Inflammatory Diseases | https://clinicaltrials.gov/study/NCT06585670 | MARiGOLD | RECRUITING | The proposed study is a block-randomized, controlled trial to evaluate the effects of a digital meditation and mindfulness practice on mental health in patients with non-infectious uveitis. | NO | Non-infectious Uveitis | OTHER: Calm Health - smartphone application | Anxiety Symptoms, The severity of anxiety symptoms of participants will be assessed by the 7-item Generalized Anxiety Disorder (GAD-7) questionnaire, which is a diagnostic self-report scale that can be used to screen for and assess the severity of Generalized Anxiety Disorder (GAD). The questionnaire asks the participa... | Depression Symptoms, The severity of depressive symptoms of participants will be assessed by the 9-item Patient Health Questionnaire (PHQ-9), which is a diagnostic self-report scale that can be used to screen for and assess the severity of depression. The questionnaire asks the participant to self-report the frequency ... | null | University of California, San Francisco | Calm.com, Inc. | ALL | ADULT, OLDER_ADULT | null | 140 | OTHER | INTERVENTIONAL | Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT | 2024-08-26 | 2025-08 | 2025-08 | 2024-09-05 | null | 2024-09-05 | UCSF, San Francisco, California, 94158, United States | null |
NCT06585657 | Brain Visual Perception Training for Prevention and Control of Premyopia | https://clinicaltrials.gov/study/NCT06585657 | null | NOT_YET_RECRUITING | The goal of this clinical trial is to investigate whether brain visual perception training can effectively prevent myopia in children with pre myopia. It will also learn about the safety of brain visual perception training.
The main questions it aims to answer are:
Does brain visual perception training slow down the ... | NO | Myopia | DEVICE: brain visual training | change in axial length after 1 year, the difference in the change of axial length between the intervention group and the control group, 1 year after the baseline | change in cycloplegic spherical equivalent after 1year, the difference in the change of cyclopegic spherical equivalent between the intervention group and the control group, 1 year after the baseline | null | Shanghai Eye Disease Prevention and Treatment Center | null | ALL | CHILD | null | 156 | OTHER | INTERVENTIONAL | Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT | 2024-09-01 | 2025-12-31 | 2026-03-31 | 2024-09-05 | null | 2024-09-05 | null | null |
NCT06585644 | A Clinical Trial of Furmonertinib Combination Therapy As Neoadjuvant Treatment in Resectable EGFR-Mutated NSCLC | https://clinicaltrials.gov/study/NCT06585644 | null | NOT_YET_RECRUITING | Evaluate the efficacy and safety of neoadjuvant furmonertinib combined with anlotinib and chemotherapy in patients with resectable stage II-III EGFR mutation-positive non-small cell lung cancer. | NO | Lung Cancer (NSCLC) | null | Objective Response Rate, According to RECIST 1.1, objective response rate (ORR) refers to the proportion of patients whose tumors have shrunk to a certain extent and maintained that response for a specific duration, including those with complete response (CR) and partial response (PR). Complete response is defined as t... | Major Pathological Response, The Major Pathological Response (MPR) is defined as the proportion of patients, among all those who have completed treatment, with less than 10% residual primary tumor under microscopic examination with hematoxylin and eosin (HE) staining., 3 Weeks|Complete Pathological Response, Complete P... | null | Shanghai Pulmonary Hospital, Shanghai, China | null | ALL | ADULT, OLDER_ADULT | null | 44 | OTHER | INTERVENTIONAL | Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT | 2024-10-01 | 2025-11-01 | 2030-06-01 | 2024-09-05 | null | 2024-09-05 | null | null |
NCT06585631 | The Collaborative Care PrTNER Study | https://clinicaltrials.gov/study/NCT06585631 | PrTNER | NOT_YET_RECRUITING | A randomized controlled trial to assess the ability of a Collaborative Care Prevention, Treatment, Navigation, Engagement, Resource (PrTNER) intervention to increase initiation of preexposure prophylaxis (PrEP) (for those at-risk for HIV) and decrease viral load (for those living with HIV) among young Black and Latino ... | NO | HIV|Substance Use Disorders|Substance Use|AIDS | BEHAVIORAL: CC PrTNER | PrEP uptake at 12 months, PrEP uptake from baseline to 12 month survey. Biomedical assessment of PrEP use at 12 months, Intraerythrocytic Tenofovir-Diphosphate (TVF-DP) from dried blood spot (DBS) \>700 fmol/punch (oral PrEP), 2+ on-time injections of Long-acting injectable cabotegravir (CAB-LA), 12 months|HIV virologi... | PrEP persistence, Duration of time participants maintain benchmark TFV-DP concentrations from baseline to 12 months, 12 months|Sustained viral suppression, Duration of time participants are virally suppressed from baseline to 12 months, 12 months|Uptake of HIV Antiretroviral therapy (ART) treatment, Frequency of inadeq... | null | Children's Hospital of Philadelphia | Johns Hopkins University|Baltimore City Health Department|National Institutes of Health (NIH)|National Institute on Drug Abuse (NIDA) | MALE | CHILD, ADULT | null | 275 | OTHER | INTERVENTIONAL | Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION | 2024-09 | 2028-06 | 2028-06 | 2024-09-05 | null | 2024-09-05 | Johns Hopkins Center for Adolescent and Young Adult Health, Baltimore, Maryland, 21205, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, 19146, United States | null |
NCT06585618 | A Multicenter Pediatric Deep Brain Stimulation Registry | https://clinicaltrials.gov/study/NCT06585618 | DBS-R | RECRUITING | There is limited data on outcomes for children who have undergone deep brain stimulation (DBS) for movement disorders, and individual centers performing this surgery often lack sufficient cases to power research studies adequately. This study aims to develop a multicenter pediatric DBS registry that allows multiple sit... | NO | Dystonia|Epilepsy in Children|Cerebral Palsy|Tourette Syndrome|Obsessive-Compulsive Disorder|Neurologic Disorder|Movement Disorders in Children|Movement Disorders|Deep Brain Stimulation | null | Development of a Multi-Center Pediatric DBS Registry, This study will define DBS as a therapeutic option for children with dystonia, other hyperkinetic movement disorders, or epilepsy., 5 years | Data Collection, Secondary objectives will focus on using the data collected to answer important research questions such as :
1. Which patients benefit from DBS?
2. Which clinical variables contribute to the responsiveness or nonresponsivness to DBS?
3. Which implant sites are preferred?
4. What are the long-term effe... | null | Boston Children's Hospital | null | ALL | CHILD, ADULT | null | 100 | OTHER | OBSERVATIONAL | Observational Model: |Time Perspective: p | 2024-07-30 | 2029-07-30 | 2029-07-30 | 2024-09-05 | null | 2024-09-05 | null | null |
NCT06585605 | A Retrospective Survey-based Multicenter Study to Delineate the Molecular and Phenotypic Spectrum of Epilepsy-dyskinesia Syndromes | https://clinicaltrials.gov/study/NCT06585605 | null | RECRUITING | The Epilepsy-Dyskinesia Study aims to advance the understanding of the clinical and molecular spectrum of epilepsy-dyskinesia syndromes, monogenic diseases that cause both movement disorders and epilepsy. Addressing challenges in rare disease research -such as small, geographically dispersed patient populations and a l... | NO | Epilepsy in Children|Dyskinesias|Movement Disorders in Children|Neurologic Disorder|Chorea|Myoclonus|Ataxia|Epilepsy|Dystonia Disorder|Movement Disorders | null | Creation of a Shared Clinical Database, The primary endpoint of this multi-center study will be the creation of the Epilepsy-Dyskinesia Study and the enrollment of 350 individuals in a shared database., 1 year|Understanding of Disease Spectrum, To comprehensively understand the spectrum and association of movement and ... | null | null | Boston Children's Hospital | null | ALL | CHILD, ADULT | null | 500 | OTHER | OBSERVATIONAL | Observational Model: |Time Perspective: p | 2024-07-01 | 2029-12-31 | 2029-12-31 | 2024-09-05 | null | 2024-09-05 | null | null |
NCT06585592 | Establishment of Multimodal-multiparametric Progressive Prediction Models for Thyroid Associated Ophthalmopathy | https://clinicaltrials.gov/study/NCT06585592 | null | COMPLETED | Thyroid-associated ophthalmopathy (TAO) is an organ-specific autoimmune disease closely related to thyroid disease, which leads the incidence of orbital disease in adults and is the most common cause of diffuse toxic goiter (Graves disease, GD). The clinical manifestations of TAO are complex and varied. In severe cases... | NO | Thyroid-Associated Ophthalmopathy | null | Percentage of participants with overall response, Overall response, 1 week after the end of treatment|Percentage of participants with overall response, Overall response, 24 weeks after the end of treatment|Percentage of participants with overall response, Overall response, 52 weeks after the end of treatment|Percentage... | Incidence and characterization of nonserious treatment emergent adverse events (TEAEs), Safety and Tolerability, 1 week after the end of treatment|Incidence and characterization of nonserious treatment emergent adverse events (TEAEs), Safety and Tolerability, 52 weeks after the end of treatment|Change of Serum TRAb, 52... | MRI, baseline|MRI, 52 weeks after the end of treatment|MRI, 1 week after the end of treatment | Shanghai Changzheng Hospital | null | ALL | ADULT, OLDER_ADULT | null | 500 | OTHER | OBSERVATIONAL | Observational Model: |Time Perspective: p | 2017-01-01 | 2024-03-31 | 2024-03-31 | 2024-09-05 | null | 2024-09-05 | null | null |
NCT06585579 | The Effect of Mucogyne® Ovule on Wound Healing (ORIGYNE) | https://clinicaltrials.gov/study/NCT06585579 | ORIGYNE | NOT_YET_RECRUITING | This clinical investigation is a post-market clinical follow-up performed to confirm the performance and safety of the Mucogyne® ovule medical device in promoting the process of wound healing, when used in accordance with its approved labelling, in the context of local cervicovaginal surgery. | NO | Cervicovaginitis | null | To confirm the performance of Mucogyne® ovule in wound healing promotion, The primary endpoint is a composite endpoint derived with the following criteria:
* Inflammation evaluated with a 5-point scale (none, mild, moderate, severe, very severe) and not assessed,
* Edema evaluated with a 5-point scale (none, mild, mod... | To assess the aspect of the epithelium 3(+1) weeks after surgery, Criteria assessing the aspect of the epithelium (such as presence of mucosa, stroma, presence and quality of mucus, opening of the cervix, presence or absence of inflammation, edema, vulvo-vaginal abrasions, coalescence, adherence, leucorrhoea and bleedi... | null | Biocodex | null | FEMALE | ADULT, OLDER_ADULT | null | 144 | INDUSTRY | INTERVENTIONAL | Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER | 2024-10 | 2025-08 | 2025-11 | 2024-09-05 | null | 2024-09-05 | null | null |
NCT06585566 | Alveolar Cleft Reconstruction With Cortical-Shells | https://clinicaltrials.gov/study/NCT06585566 | null | NOT_YET_RECRUITING | The main goal of the secondary alveolar bone grafting (SABG) for alveolar clefts is the rehabilitation of the disorganized maxilla, aiming to stabilize the maxillary foundation as a solid functional mass that would abort growth disturbance, allow for teeth eruption, and enhance their orthodontic movements.
The study e... | NO | Alveolar Cleft | PROCEDURE: Cortical-shell graft | Vertical bone loss, The amplitude of radiographic vertical bone loss, 6 months consolidation period | Horizontal bone width, The amplitude of radiographic the horizontal bone width, 6 months consolidation period|Bone density, The radiographic bone density of the consolidated graft at the site of the reconstructed cleft, 6 months consolidation period | null | Beni-Suef University | null | ALL | CHILD | null | 10 | OTHER | INTERVENTIONAL | Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT | 2024-10-01 | 2025-08-01 | 2025-10-01 | 2024-09-05 | null | 2024-09-05 | null | null |
NCT06585553 | Atrophic Gastritis and OLGIM Stage | https://clinicaltrials.gov/study/NCT06585553 | null | COMPLETED | Three clinical research coordinators recruited patients aged 40-75 who underwent screening endoscopy at the Digestive Endoscopy Center of Qilu Hospital from July 1, 2022, to July 30, 2024. All participating patients provided written informed consent. Baseline information such as height, weight, age, sex, smoking and al... | NO | Intestinal Metaplasia | null | Diagnostic Performance of IM at Different Sites, Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of IM at different gastric sites for predicting OLGIM stage III/IV were calculated., 3 years | null | null | Shandong University | null | ALL | ADULT, OLDER_ADULT | null | 2,121 | OTHER | OBSERVATIONAL | Observational Model: |Time Perspective: p | 2022-07-01 | 2024-07-30 | 2024-08-25 | 2024-09-05 | null | 2024-09-05 | null | null |
NCT06585540 | A Pilot Study to Evaluate Barhemsys for the Prevention of Postoperative Nausea and Vomiting in the Bariatric Surgery Population | https://clinicaltrials.gov/study/NCT06585540 | null | NOT_YET_RECRUITING | The purpose of this study is to evaluate the drug, Barhemsys (Amisulpride), on Postoperative Nausea and Vomiting following Bariatric surgery. Postoperative nausea and vomiting is any nausea or vomiting that occurs within 24 hours following surgery.
Barhemsys is approved for the treatment and prevention of Postoperativ... | NO | Post Operative Nausea and Vomiting | null | Number of Participants With "Complete Response" in the Post Anesthesia Care Unit, Complete response is defined as no occurrence of vomiting or retching, no nausea score ≥ 1 and no use of rescue medication during their Post Anesthesia Care Unit stay., Until Patient Leaves Post Anesthesia Care Unit (60-120 minutes) | Incidence of complete response to established Post-operative Nausea and Vomiting, Effectiveness of Barhemsys in the treatment of established nausea or vomiting in the high-risk bariatric surgical population during Post Anesthesia Care Unit stay. Failure of complete response is defined as subject emesis or use of rescue... | null | Benaroya Research Institute | null | ALL | ADULT, OLDER_ADULT | null | 100 | OTHER | INTERVENTIONAL | Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (PARTICIPANT)|Primary Purpose: PREVENTION | 2024-09-09 | 2025-09 | 2026-01 | 2024-09-05 | null | 2024-09-05 | null | null |
NCT06585527 | Clinical Study on the Safety and Efficacy of TS-2021 in the Treatment of Recurrent Malignant Glioma | https://clinicaltrials.gov/study/NCT06585527 | null | RECRUITING | The goal of this clinical trial is to evaluate the safety and efficacy of oncolytic virus TS-2021 in the treatment of recurrent malignant glioma.About 30 eligible participants with recurrent malignant glioma will :
* Be intratumoral injected the TS-2021 oncolytic virus to study its safety and efficacy.
* Be followed f... | NO | Glioblastoma Multiforme|Glioma, Malignant | null | Incidence and severity of adverse events., All events with a Grade 3 or above toxicity (defined by the CTCAE v4.0) will be tabulated by event and by relationship to TS-2021., Up to 8 weeks|Overall survival, The overall survival for each patient receiving TS-2021 will be calculated., Up to 12 months | Objective response rate (ORR) determined by MRI scan review., Interval tumor size change will be measured., Up to 12 months|Progression Free Survival., Time after TS-2021 administration to clinical and radiographic disease progression, Up to 12 months | null | Beijing Neurosurgical Institute | null | ALL | ADULT, OLDER_ADULT | null | 30 | OTHER | INTERVENTIONAL | Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT | 2024-08-29 | 2026-01-01 | 2026-01-01 | 2024-09-05 | null | 2024-09-05 | null | null |
NCT06585514 | Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Systemic Lupus Erythematosus | https://clinicaltrials.gov/study/NCT06585514 | null | NOT_YET_RECRUITING | The goal of this study is to evaluate the safety and efficacy of CD19 CAR T cells in the treatment of Systemic lupus erythematosus (SLE). | NO | Systemic Lupus Erythematosus (SLE)|Lupus Nephritis (LN) | null | Phase I: Dose-limiting toxicity (DLT), The incidence and type of dose-limiting toxicity (DLT)., 28 days post infusion|Phase I: Adverse events (AEs), The incidence and severity of adverse events (AE)., 30 days post infusion|Phase II: Objective response rate (ORR), Proportions of subjects achieving SLE Responder Index (S... | Phase I: Objective response rate (ORR), Proportions of subjects achieving SLE Responder Index (SRI)-4 response., 3 months and 6 months|Phase I: Long-term Adverse events (AEs), Total number, incidence and severity of AEs from 30 days to 2 years after CD19 CAR T infusion will be recorded., From 30 days after CD19 CAR T i... | null | Beijing GoBroad Hospital | null | ALL | CHILD, ADULT, OLDER_ADULT | null | 18 | OTHER | INTERVENTIONAL | Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT | 2024-10-01 | 2025-09-30 | 2025-12-31 | 2024-09-05 | null | 2024-09-05 | null | null |
NCT06585501 | A Study of Treatment Patterns in HER2-positive Unresectable and Advanced Gastric/ Gastroesophageal Junction Cancer in China | https://clinicaltrials.gov/study/NCT06585501 | REHEARSAL | ENROLLING_BY_INVITATION | This study will be conducted to retrospectively evaluate the treatment patterns in first-line, second-line, and subsequent lines of therapy for HER2-positive Gastric Cancer/Gastroesophageal Junction Cancer (GC/GEJC) patients. | NO | Gastric Cancer|Gastroesophageal Junction Cancer | OTHER: No drug | Percentage of patients receiving first-line, second-line, and third-line anti-tumor regimens, 72 months | Percentage of HER2 sample type and testing method among patients with a first diagnosis of locally advanced or metastatic HER2-positive GC/GEJC, 72 months|Percentage of re-biopsies and re-biopsies with HER2-positive results among patients with a first diagnosis of locally advanced or metastatic HER2-positive GC/GEJC, 7... | null | Daiichi Sankyo | null | ALL | ADULT, OLDER_ADULT | null | 800 | INDUSTRY | OBSERVATIONAL | Observational Model: |Time Perspective: p | 2024-08-15 | 2025-03-31 | 2025-03-31 | 2024-09-05 | null | 2024-09-05 | Beijing Cancer Hospital, Beijing, China|The First Affiliated Hospital of Fujian Medical University, Fuzhou, China|Zhejiang Provincial People's Hospital, Hangzhou, China|Harbin Medical University Cancer Hospital, Harbin, China|Affiliated Cancer Hospital of Shandong First Medical University, Jinan, China|Liaoning Cancer ... | null |
NCT06585488 | A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants with Advanced or Metastatic Solid Tumors with KRAS Mutations or Amplification | https://clinicaltrials.gov/study/NCT06585488 | null | NOT_YET_RECRUITING | This is a first-in-human (FIH), open-label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BGB-53038 as monotherapy in participants with advanced or metastatic solid tumors harboring KRAS mutation... | NO | Metastatic Solid Tumors|Advanced Non-squamous Non-small-cell Lung Cancer|Advanced Colorectal Cancer|Advanced Pancreatic Ductal Adenocarcinoma|Advanced Gastric Cancer|Advanced Gastroesophageal Junction Cancer|Advanced Esophageal Adenocarcinoma | null | Phase 1a: Number of Participants Experiencing Adverse Events (AEs), Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) characterized by type, frequency, severity (as graded by the National Cancer Institute-Common Terminology Criteria for Adverse Events \[NCICTCAE\] V... | Phase 1a: Single-dose and steady-state area under the concentration-time curve (AUC) of BGB-53038, Up to approximately 2 years|Phase 1a: Single-dose and steady-state Half-life (t1/2) of BGB-53038, Up to approximately 2 years|Phase 1a: Single-dose and steady-state maximum observed plasma concentration (Cmax) of BGB-5303... | null | BeiGene | null | ALL | ADULT, OLDER_ADULT | null | 177 | INDUSTRY | INTERVENTIONAL | Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT | 2024-12 | 2026-12 | 2026-12 | 2024-09-05 | null | 2024-09-05 | null | null |
NCT06585475 | Investigation of the Effectiveness of Structured Education According to Premenstrual Syndrome Symptom Map | https://clinicaltrials.gov/study/NCT06585475 | null | COMPLETED | In this study, it was aimed to evaluate the effectiveness of the training structured according to the PMS symptom map. This experimental (randomised-controlled) study was conducted with women of reproductive age with PMS. Women who met the inclusion criteria and volunteered to participate in the study constituted the s... | NO | Premenstrual Syndromes|Education|Menstrual Cycle Disorder | BEHAVIORAL: Structured training according to premenstrual syndrome symptom map | Premenstrual syndrome assessment scale, a scale used to measure the degree of premenstrual syndrome, pre-intervention, 2 month after intervention|premenstrual syndrome specific life satisfaction scale, Premenstrual syndrome specific life satisfaction scale evaluates life satisfaction of women with PMS, pre-intervention... | null | null | Sakarya University | null | FEMALE | ADULT | null | 101 | OTHER | INTERVENTIONAL | Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE | 2023-11-01 | 2024-06-10 | 2024-08-05 | 2024-09-05 | null | 2024-09-05 | Sakarya University, Sakarya, 54050, Turkey | null |
NCT06585462 | Single and Multiple Ascending Dose Study of AMG 513 in Participants With Obesity | https://clinicaltrials.gov/study/NCT06585462 | null | NOT_YET_RECRUITING | The primary objective of this study is to assess the safety and tolerability of AMG 513 after single and multiple doses. | NO | Cardiometabolic Disease | DRUG: AMG 513|DRUG: Placebo | Number of Participants With Treatment-emergent Adverse Events (TEAE), Approximately 178 days (Part A) and 225 days (Part B) | Maximum Observed Drug Concentration (Cmax) of AMG 513, Day 1 up to Day 57|Time to Cmax (Tmax) of AMG 513, Day 1 up to Day 57|Area Under the Concentration-time Curve (AUC) of AMG 513, Day 1 up to Day 57 | null | Amgen | null | ALL | ADULT, OLDER_ADULT | null | 80 | INDUSTRY | INTERVENTIONAL | Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT | 2024-09-16 | 2026-03-17 | 2026-03-17 | 2024-09-05 | null | 2024-09-05 | null | null |
NCT06585449 | A Study to Evaluate ALN-HTT02 in Adult Patients With Huntington's Disease | https://clinicaltrials.gov/study/NCT06585449 | null | NOT_YET_RECRUITING | The purpose of this study is to evaluate the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of a single dose of ALN-HTT02. | NO | Huntington's Disease | DRUG: ALN-HTT02|DRUG: Placebo | Frequency of Adverse Events (AEs) in the Double-blind Part of the Study, Up to 12 months|Frequency of AEs in the Open-label Part of the Study, Up to 12 months | Change from Baseline in Levels of Mutant Huntingtin (mHTT) in Cerebrospinal Fluid (CSF), Baseline up to Month 12 in the Double-blind Part of the study; Baseline up to Month 12 in the Open-label Part of the study|Concentrations of ALN-HTT02 in Plasma, Area Under the Plasma Concentration-time Curve (AUC) Maximum Observed... | null | Alnylam Pharmaceuticals | null | ALL | ADULT, OLDER_ADULT | null | 54 | INDUSTRY | INTERVENTIONAL | Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT | 2024-09-30 | 2027-12-15 | 2028-07-05 | 2024-09-05 | null | 2024-09-05 | null | null |
NCT06585436 | Selective Versus Stepwise Removal of Deep Carious Lesions in Permanent Teeth Using Different Medicaments | https://clinicaltrials.gov/study/NCT06585436 | null | COMPLETED | The study involved 54 adult patients between the ages of 18 and 50 years who had a posterior permanent tooth with a deep occlusal (Class I) carious lesion that extended to the inner third of the dentin (D3) and divided them into two equal groups randomly (N=27) according to the caries removal technique: group 1 (SE), a... | NO | Caries Arrested | PROCEDURE: partial caries removal | post operative pain, evaluation of the post operative pain following restorations using modified USPHS, 7 days|post operative pain, evaluation of the post operative pain following restorations using modified USPHS, 3 months|post operative pain, evaluation of the post operative pain following restorations using modified... | null | null | Al-Azhar University | null | ALL | ADULT | null | 54 | OTHER | INTERVENTIONAL | Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT | 2023-02-01 | 2024-05-01 | 2024-08-01 | 2024-09-05 | null | 2024-09-05 | Al Azhar university, Cairo, 11651, Egypt | null |
NCT06585423 | Tolerability of an Anesthesia-free Tonometer Tip | https://clinicaltrials.gov/study/NCT06585423 | null | NOT_YET_RECRUITING | The purpose of this study is to compare the tolerability and comfort of 3 different prototype anesthesia-free tonometer tips with the standard tonometer tip in conjunction with anesthesia. The best-tolerated prototype anesthesia-free tonometer tip will be identified for further development for home tonometry. | NO | Glaucoma | DIAGNOSTIC_TEST: Sterile commercially available bandage contact lens|DIAGNOSTIC_TEST: Medical grade silicone of a thickness <100 µm|DIAGNOSTIC_TEST: Medical grade silicone of a thickness >100 µm | Patient tolerability rating of different tips, Tolerability of 3 different prototype anesthesia-free tonometer tips with the standard tonometer tip, Baseline|Patient comfort rating of different tips, Comfort of 3 different prototype anesthesia-free tonometer tips with the standard tonometer tip, Baseline | null | null | Duke University | null | ALL | ADULT, OLDER_ADULT | null | 50 | OTHER | INTERVENTIONAL | Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC | 2024-10 | 2025-10 | 2025-10 | 2024-09-05 | null | 2024-09-05 | Duke Eye Center, Durham, North Carolina, 27710, United States | null |
NCT06585410 | Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma | https://clinicaltrials.gov/study/NCT06585410 | null | NOT_YET_RECRUITING | This study will test a study drug called cemiplimab to see if it can help treat early-stage cutaneous squamous cell carcinoma (CSCC), a type of skin cancer. Cemiplimab works by helping the immune system to kill cancer cells. It binds to a protein called programmed cell death-1 (PD-1) on the surface of certain immune ce... | NO | Cutaneous Squamous Cell Carcinoma (CSCC) | DRUG: Cemiplimab|PROCEDURE: Standard of care | Event-Free Survival (EFS) as assessed by the investigator, Up to 1 year|EFS as assessed by the investigator, Up to 3 years | Composite Complete Response (CCR) for Target Lesion (TL), Experimental Arm, At week 13|Non-Target Lesions (NTLs) in the Region of the Target Lesion (ROTL), Experimental Arm, Baseline and at week 13|Incidence of Treatment Emergent Adverse Events (TEAEs), Up to 3 years|Severity of TEAEs, Up to 3 years|Size of surgical de... | null | Regeneron Pharmaceuticals | null | ALL | ADULT, OLDER_ADULT | null | 369 | INDUSTRY | INTERVENTIONAL | Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT | 2025-01-28 | 2029-06-03 | 2029-06-03 | 2024-09-05 | null | 2024-09-05 | null | null |
NCT06585397 | ICF-Based Evaluation of the Upper Extremity in Children With Quadriparetic Cerebral Palsy | https://clinicaltrials.gov/study/NCT06585397 | null | COMPLETED | Cerebral palsy (CP) is a neurodevelopmental disorder characterized by abnormalities in muscle tone, movement, and motor skills resulting from permanent, non-progressive damage to the developing brain before, during, or after birth. The worldwide prevalence of CP is 2-3 per 1000 live births. Spastic CP accounts for appr... | NO | Upper Extremity Spasticity|Quadriplegic Cerebral Palsy | OTHER: Grup 1 | Modified Ashworth Scale (MAS), It is a 6-point scale that measures the resistance of the muscle to passive movement by passively moving it through the normal range of motion of the joint. Within the scope of the study, the upper extremity muscles; shoulder flexors, shoulder extensors, elbow flexors, elbow extensors, fo... | null | null | Acıbadem Atunizade Hospital | null | ALL | CHILD | null | 20 | OTHER | OBSERVATIONAL | Observational Model: |Time Perspective: p | 2024-08-01 | 2024-09-01 | 2024-09-01 | 2024-09-05 | null | 2024-09-05 | Acıbadem Altunizade Hospital, İstanbul, AA, 34662, Turkey | null |
NCT06585384 | Safety of a Strategy Combining Etanercept Administration with Repeated Contrast Ultrasound in Patients with Alzheimer's Disease | https://clinicaltrials.gov/study/NCT06585384 | BRAINWAVES | NOT_YET_RECRUITING | Alzheimer's disease (AD) is a clinico-pathological entity combining multiple and varied neuropathological lesions with characteristic abnormal accumulations (amyloid Beta (Aβ) plaques and neurofibrillary degeneration (NFD)), neuroinflammation, as well as neuronal and synaptic suffering.
To date, only symptomatic treat... | NO | Alzheimer Disease | null | To assess the safety of a strategy combining 9 weeks of etanercept administration with 5 weeks of repeated contrast ultrasound of 2 sessions per day, 5 days per week (from the fifth week of etanercept treatment) in patients with Alzheimer's disease., Number of patients presenting related adverse events (CTCAE v4.0)... | null | null | Fondation Ophtalmologique Adolphe de Rothschild | null | ALL | ADULT, OLDER_ADULT | null | 5 | NETWORK | INTERVENTIONAL | Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT | 2025-03 | 2027-09 | 2027-09 | 2024-09-05 | null | 2024-09-05 | null | null |
NCT06585371 | Evaluation of a 6-month Intragastric Balloon | https://clinicaltrials.gov/study/NCT06585371 | null | NOT_YET_RECRUITING | Post-market observational, adaptive, single-arm clinical study to evaluate the percentage of total weight loss after treatment with an intragastric balloon. Patients will be followed for 6 months after the device is installed. | NO | Obesity and Overweight | null | Evaluation of the percentage of total weight loss (%PPT) in 6 months after installation of the intragastric balloon, To analyze the percentage of total weight loss 6 months after installation of the intragastric balloon, the following formula will be used:
Percentage of total weight loss = kilos lost/initial weight x ... | Number of Adverse event occurrence assessed by clinical evaluation, Adverse event monitoring through medical clinical evaluation, From the installation of the balloon to the end of treatment at 6 months|Weight changes 6 months after installation of the balloon assessed by anthropometric balance in in-person consultatio... | null | MEDICONE PROJETOS E SOLUCOES PARA A INDUSTRIA E A SAUDE LTDA | null | ALL | ADULT, OLDER_ADULT | null | 46 | OTHER | OBSERVATIONAL | Observational Model: |Time Perspective: p | 2024-09-15 | 2025-03-15 | 2025-10-31 | 2024-09-05 | null | 2024-09-05 | null | null |
NCT06585358 | DoseTB-individualised Dosing by Model-informed Precision Dosing for Pulmonary Tuberculosis | https://clinicaltrials.gov/study/NCT06585358 | DoseTB | NOT_YET_RECRUITING | The goal of this observational study is to investigate whether model-informed precision dosing (MIPD), as a clinical support for early individualised dosing in addition to the national TB care program, can optimise the drug exposure of TB drugs during TB treatment.
Main research questions:
In adult patients with drug... | NO | Tuberculosis, Pulmonary | null | Proportion of predicted dose, Proportion of participants with predicted doses of rifampicin, isoniazid and/or pyrazinamide within 5 days from sampling (%), Within the first 5 days from sampling | Proportion reaching predicted drug exposure, For participants with dose-predicted treatment, proportion who will reach the target levels for rifampicin, isoniazid and/or pyrazinamide after MIPD, Through study completion, an average of one month|Model precision, Precision of the model comparing predicted drug levels to ... | null | Karolinska Institutet | null | ALL | ADULT, OLDER_ADULT | null | 30 | OTHER | OBSERVATIONAL | Observational Model: |Time Perspective: p | 2024-10-01 | 2026-10 | 2027-09 | 2024-09-05 | null | 2024-09-05 | null | null |
NCT06585345 | Clinical Study on the Safety and Efficacy of CD7 CAR-T Cell in Patients With Relapsed/Refractory Acute Leukemia | https://clinicaltrials.gov/study/NCT06585345 | null | RECRUITING | Acute leukemia is a malignant clonal disease of hematopoietic stem cells. At present, the treatment for acute leukemia is relatively limited, and it is still based on high-intensity chemotherapy drug therapy and hematopoietic stem cell transplantation. The prognosis of recurrent and refractory acute leukemia is poor, a... | NO | Acute-Leukemia | BIOLOGICAL: CD7 CAR-T cell | Number of Adverse Events, Adverse events are evaluated with CTCAE V4.03, 12 months|Overall response rate (ORR), ORR includes CR, CRi, MLFS and PR. Complete remission (CR)#Bone marrow blasts \<5%; absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease; absolute neutrophil count \>1.0x... | Duration of overall response (DOR), Duration of overall response will be assessed from the CAR-T cell infusion to progression, death or last follow-up, 24 months|Progression-free survival(PFS), PFS will be assessed from the CAR-T cell infusion to progression, death or last follow-up., 24 months|Overall survival(OS), OS... | the duration of CAR T-cells in vivo, the time of CAR-T cells' persistence in blood and the copies of CAR-T cells, 24 months|CAR-T related cytokine expression, CAR-T related cytokine expression, 24 months | The General Hospital of Western Theater Command | YakeBiotech Ltd. | ALL | CHILD, ADULT, OLDER_ADULT | null | 200 | OTHER | INTERVENTIONAL | Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT | 2024-02-18 | 2027-12-31 | 2030-11-01 | 2024-09-05 | null | 2024-09-05 | The General Hospital of Western Theater Command, Chengdu, Sichuan, China | null |
NCT06585332 | Handgrip and Respiratory Dysfunction in HD Patients. | https://clinicaltrials.gov/study/NCT06585332 | null | RECRUITING | Hereditary neurodegenerative diagnosis of Huntington's disease (HD) is associated with a progressive deterioration of the respiratory system function . This fact contributes strongly to the increased risk of aspiration pneumonia as a primary cause of death in people with HD. But regularly objective monitoring of the ai... | NO | Huntington Disease | null | Maximal Hand grip strength, Unit of Measure: kg Assessment followed recommendation of The American Society of Hand Therapists. HSG is measured using DHD-1 digital hand dynamometer (SAEHAN®,Seahan Corporation)., Up to 35 weeks (once on a single screening visit)|Voluntary peak cough flow, Unit of measure: l/min Assessmen... | Index of Pulmonary dysfunction, Questionnaire of four questions. Scale range: 0-11 points A higher score indicates a worse pulmonary condition., Up to 35 weeks (once on a single screening visit) | null | General University Hospital, Prague | null | ALL | ADULT, OLDER_ADULT | null | 70 | OTHER | OBSERVATIONAL | Observational Model: |Time Perspective: p | 2024-04-01 | 2024-10 | 2024-10 | 2024-09-05 | null | 2024-09-05 | null | null |
NCT06585319 | Pirfenidone LP or Collagen-polyvinylpyrrolidone in COVID-19 | https://clinicaltrials.gov/study/NCT06585319 | null | COMPLETED | Collagen-polyvinylpyrrolidone (collagen-PVP) and pirfenidone have the ability to control cytokine storms. This work explores the therapeutic effects of both, on the early treatment of patients with severe COVID-19. The hospital stay, quick COVID-19 severity index (qCSI) and admission to the ICU were statistically signi... | NO | COVID 19 | DRUG: Collagen-polyvinylpyrrolidone|DRUG: Pirfenidone 1200 mg | Number of patients that survived the COVID-19 infection, After each of the treatments that were given for seven days, the evolution of the patients was recorded., From enrollment until one month of follow up | null | null | Materno-Perinatal Hospital of the State of Mexico | null | ALL | ADULT, OLDER_ADULT | null | 36 | OTHER | INTERVENTIONAL | Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT | 2020-02-01 | 2021-06-30 | 2024-08-31 | 2024-09-05 | null | 2024-09-05 | Monica Pretelini Saenz Maternal Perinatal Hospital, Toluca, State Of Mexico, 50120, Mexico | null |
NCT06585306 | High-flow Nasal Oxygen Therapy in Obese Patients Undergoing Sedative Gastroscopy | https://clinicaltrials.gov/study/NCT06585306 | null | NOT_YET_RECRUITING | Obese patients often have fat accumulation in the head and neck, increased soft tissue in the oropharynx, decreased lung compliance, decreased lung volume and residual volume, and some obese patients also suffer from obstructive sleep apnea. Therefore, obese patients may experience hypoxemia during sedative gastroscopy... | NO | Hypoxia|Obesity|Gastrostomy | BEHAVIORAL: jaw lift, increasing oxygen flow, mask ventilation, intubation | incidence of hypoxia, 75% ≤ SpO2 \< 90% for \<60 s, through gastroscopy completion, an average of 6min | incidences of subclinical respiratory depression and severe hypoxia, (90% ≤ SpO2 \< 95%) and (SpO2 \< 75% for any duration or 75% ≤ SpO2 \< 90% for ≥60 s), through gastroscopy completion, an average of 6min|occurrence of adverse reactions other than hypoxia, body movements, vomiting, reflux, bronchospasm, through gastr... | null | XiaoLiang Wang | null | ALL | ADULT, OLDER_ADULT | null | 882 | OTHER | INTERVENTIONAL | Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: PREVENTION | 2024-10-10 | 2025-09-20 | 2025-10-20 | 2024-09-05 | null | 2024-09-05 | Nanjing First Hospital, Nanjing, Jiangsu, 210006, China | null |
NCT06585293 | Comparability of Fingerprick vs Venous Blood for Tacrolimus Monitoring | https://clinicaltrials.gov/study/NCT06585293 | null | NOT_YET_RECRUITING | Organ transplant rejection occurs when the immune system attacks the transplanted organ. To prevent rejection, transplant-patients are given immunosuppressant drugs which can suppress the immune system from attacking the transplanted organ. Patients who have had a kidney-transplant take immunosuppressant drugs such as ... | NO | Immunosuppression | DEVICE: Mitra Microsampling Device | Validation of an in-house LC-MS/MS method and L4L-Analyst quantitative software for the measurement of tacrolimus and creatinine using capillary fingerprick samples collected with a Mitra device., Validation of an in-house LC-MS/MS method for the measurement of tacrolimus and creatinine using capillary fingerprick samp... | Questionnaire to assess whether the new sample collection method improves patient experience, Patient satisfaction questionnaire using a 5-point likert scale, 6 months | null | Nottingham University Hospitals NHS Trust | null | ALL | CHILD, ADULT, OLDER_ADULT | null | 50 | OTHER | OBSERVATIONAL | Observational Model: |Time Perspective: p | 2024-09-01 | 2025-02-01 | 2025-02-01 | 2024-09-05 | null | 2024-09-05 | Nottingham University Hospitals NHS Trust, Nottingham, NG7 2UH, United Kingdom | null |
NCT06585280 | Assistive Device Satisfaction | https://clinicaltrials.gov/study/NCT06585280 | null | NOT_YET_RECRUITING | Assistive devices are of critical importance for the independence and participation of disabled individuals in society and there is an increasing interest in them today. When the literature is examined, it is seen that there are few studies evaluating the use of orthotic and prosthetic assistive devices in terms of pat... | NO | Assistive Technology|Orthosis|Prosthesis|Device | null | Quebec User Evaluation of Satisfaction with Assistive Technology (QUEST), The Quebec User Evaluation of Satisfaction with Assistive Technology (QUEST) is a survey used to assess the satisfaction of individuals using technological assistive devices. The first version of the survey, developed by Demers et al. in 1996 to ... | null | null | Istanbul Medipol University Hospital | null | ALL | ADULT, OLDER_ADULT | null | 200 | OTHER | OBSERVATIONAL | Observational Model: |Time Perspective: p | 2024-09-15 | 2024-10-15 | 2024-10-15 | 2024-09-05 | null | 2024-09-05 | null | null |
NCT06585267 | Development of a New Patient Reported Outcome Measure (PROM) to Assess Patient's Emotional Wellbeing, and Perceptions of Total Knee Replacement Surgery for the Treatment of Knee Arthritis | https://clinicaltrials.gov/study/NCT06585267 | SYNC01- P4 | NOT_YET_RECRUITING | Development of a new Patient Reported Outcome Measure (PROM) to assess patient's emotional wellbeing, and perceptions of Total Knee Replacement surgery for the treatment of knee arthritis. | NO | Complete Questionnaires Following TKR Surgery | null | Validate final questionnaire, Validation of final questionnaire, From first post-op visit to 12month follow-up | null | null | Invibio Ltd | Oxford University Innovation | ALL | ADULT, OLDER_ADULT | null | 150 | INDUSTRY | OBSERVATIONAL | Observational Model: |Time Perspective: p | 2024-10-01 | 2025-12-31 | 2025-12-31 | 2024-09-05 | null | 2024-09-05 | null | null |
NCT06585254 | tVNS in Long COVID-19 | https://clinicaltrials.gov/study/NCT06585254 | null | RECRUITING | A prior open label study has shown that transcutaneous vagus nerve stimulation \[tVNS\] can improve the health of some patients with postacute sequelae of SARS-CoV-2 infection (PASC), severely affected enough to also fulfill criteria for myalgic encephalomyelitis / chronic fatigue syndrome (ME/CFS). The purpose of this... | NO | Long Covid Also Fulfilling Criteria for Chronic Fatigue Syndrome | DEVICE: Transcutaneous vagus nerve stimulator | The Chalder Fatigue Questionnaire (CFQ), The Chalder Fatigue Questionnaire (CFQ) is used as a measure of fatigue. The CFQ consists of 11 items and uses likert scoring 0, 1, 2, 3, providing a full scale range of 0-33, where lowest score is least fatigue., End of 6 week|Change in Short Form Health Survey (SF-36), The SF-... | Heart Rate Variability, Participants will attach a device invented by the co-investigator which detects ECG and can quantify R-R intervals compute root mean square of successive differences (RMSSD) between normal heartbeats. The RMSSD reflects the beat-to-beat variance in heart rate and is the primary time-domain measu... | null | Icahn School of Medicine at Mount Sinai | null | ALL | ADULT, OLDER_ADULT | null | 50 | OTHER | INTERVENTIONAL | Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT | 2024-09 | 2026-12-31 | 2026-12-31 | 2024-09-05 | null | 2024-09-05 | Icahn School of Medicine at Mount Sinai, New York, New York, 10029, United States | null |
NCT06585241 | A Study to Investigate the Immunogenicity of mRNA COVID-19 Variant-containing Vaccine Formulations in Adults to Prevent COVID-19 | https://clinicaltrials.gov/study/NCT06585241 | null | NOT_YET_RECRUITING | The purpose of this study is to investigate the immunogenicity of mRNA COVID-19 variant-containing vaccine formulations against the vaccine matched variants and newly emerged variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in previously vaccinated adults. | NO | SARS-CoV-2 | BIOLOGICAL: mRNA-1273 Variant-containing Formulation | Geometric Mean Value of Neutralizing Antibody Against COVID-19 Variants, Day 29|Geometric Mean Fold Rise of Neutralizing Antibody Against COVID-19 Variants, Day 29 | Number of Participants with Serious Adverse Events (AEs), AEs Leading to Study Withdrawal, and AEs of Special Interest, Day 1 through Day 29 | null | ModernaTX, Inc. | null | ALL | ADULT, OLDER_ADULT | null | 100 | INDUSTRY | INTERVENTIONAL | Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION | 2024-09-06 | 2024-10-29 | 2025-10-29 | 2024-09-05 | null | 2024-09-05 | null | null |
NCT06585228 | Detecting Cardiac Thrombi in Acute Ischemic Stroke on Cardiac CT Versus Transoesophageal Echocardiography | https://clinicaltrials.gov/study/NCT06585228 | MtH-DETECT | RECRUITING | Rationale:
Cardiac CT acquired during the acute stroke imaging protocol (acute cardiac CT) has recently been shown to have a superior diagnostic yield than transthoracic echocardiography, which is currently the most commonly used method to screen for structural sources of cardioembolism in patients with acute ischemic... | NO | Ischemic Stroke|Cardioembolic Stroke|Thrombus; Embolism|Left Atrial Thrombosis|Left Atrial Appendage Thrombosis | DIAGNOSTIC_TEST: Cardiac Computed Tomography|DIAGNOSTIC_TEST: Transesophageal echocardiography|DIAGNOSTIC_TEST: Repeated Cardiac Computed Tomography | Proportion of patients with a left atrial thrombus, The proportion of patients with a LA thrombus detected on acute cardiac CT that dissolves in the first days after stroke, defined as thrombi that are seen on initial cardiac CT but are no longer visible on TEE and repeated cardiac CT., The assessment of a left atrial ... | Other pre-defined high-risk and non-high-risk sources of embolism on cardiac CT and TEE, Other high-risk and non-high-risk sources that have been detected on cardiac CT and TEE., Cardiac CT is performed and assessed when the patients arrives at the Emergency Department. The TEE is performed <7 days after the cardiac CT... | null | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | null | ALL | ADULT, OLDER_ADULT | null | 39 | OTHER | OBSERVATIONAL | Observational Model: |Time Perspective: p | 2024-09-01 | 2026-07-01 | 2026-10-01 | 2024-09-05 | null | 2024-09-05 | Amsterdam University Medical Center (UMC), Amsterdam, Noord-Holland, 1105AZ, Netherlands | null |
NCT06585215 | Standardization of Physician-Modified Stent Grafts for Abdominal Aortic Aneurysms | https://clinicaltrials.gov/study/NCT06585215 | RESTORE | ENROLLING_BY_INVITATION | This study explores the use of physician-modified stent grafts (PMSGs) for treating abdominal aortic aneurysms that are unsuitable for open surgery or standard endovascular grafts. Custom-made fenestrated endografts are not viable in urgent or symptomatic cases due to lengthy manufacturing times. Although off-the-shelf... | NO | Abdominal Aortic Aneurysm|Endovascular Procedures|Stents|Vascular Surgical Procedures | null | Expert Consensus on PMSG Indications and Techniques, To achieve expert consensus on aspects regarding indications, planning and performing PMSGs in the treatment of abdominal aortic aneurysms, as determined by the completion of a modified Delphi consensus., 30.06.2025 | Survey-Based Review of PMSG Strategies and Techniques, To conduct a survey-based scoping review to identify the predominant strategies and techniques utilized in the execution of PMSGs for interventions on abdominal aortic aneurysms., 30.06.2025|Comparison of 3D-Printed Models and CT-Based Planning, To test the hypothe... | null | Ente Ospedaliero Cantonale, Bellinzona | null | ALL | CHILD, ADULT, OLDER_ADULT | null | 100 | OTHER | OBSERVATIONAL | Observational Model: |Time Perspective: p | 2014-06-14 | 2025-06-30 | 2025-06-30 | 2024-09-05 | null | 2024-09-05 | Centro Vascolare Ticino, Servizio di Chirurgia Vascolare e Angiologia, Lugano, Ticino, 6900, Switzerland | null |
NCT06585202 | Study of ATI-2138 in Adult Participants With Moderate to Severe Atopic Dermatitis | https://clinicaltrials.gov/study/NCT06585202 | null | RECRUITING | This is a Phase 2 open label study of ATI-2138 in participants with moderate to severe atopic dermatitis. | NO | Atopic Dermatitis | DRUG: ATI-2138 | Incidence and severity of treatment emergent adverse events (TEAEs), From baseline up to two weeks after treatment (Day 98) | Change from baseline Eczema Area and Severity Index (EASI) Over Time, Up to Week 12|Proportions of participants who achieve at least 50%, 75%, and 90% improvement in EASI Over Time, Up to Week 12|Proportion of participants achieving Investigator's Global Assessment-Treatment Success Over Time, Up to Week 12|Change in I... | null | Aclaris Therapeutics, Inc. | null | ALL | ADULT | null | 15 | INDUSTRY | INTERVENTIONAL | Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT | 2024-08-19 | 2025-04 | 2025-05 | 2024-09-05 | null | 2024-09-05 | Aclaris Investigational Site, Encino, California, 91436, United States|Aclaris Investigational Site, San Diego, California, 92123, United States|Aclaris Investigational Site, Plainfield, Indiana, 46168, United States|Aclaris Investigational Site, Austin, Texas, 78759, United States|Aclaris Investigational Site, San Ant... | null |
NCT06585189 | CARE Initiative: Real-world Emulation of the KEYNOTE-189 Trial [DS4] | https://clinicaltrials.gov/study/NCT06585189 | null | COMPLETED | The goal of this non-interventional study is to emulate the KEYNOTE-189 randomized controlled trial of pembrolizumab for the treatment of metastatic non-small cell lung cancer using real-world, electronic health record data. The main questions this study aims to answer are:
1. Do patients with metastatic non-small cel... | NO | Metastatic Non Small Cell Lung Cancer | DRUG: Pembrolizumab|DRUG: Pemetrexed|DRUG: Cisplatin|DRUG: Carboplatin | Real-world overall survival (rwOS), Time from study treatment initiation to death, Study treatment initiation to death or censoring|Real-world progression-free survival (rwPFS), Time from study treatment initiation to disease progression or death, Study treatment initiation to disease progression, death, or censoring | null | null | Aetion, Inc. | AbbVie|Amgen|AstraZeneca|Bayer|Gilead Sciences|Janssen, LP|Pfizer | ALL | ADULT, OLDER_ADULT | null | 304 | OTHER | OBSERVATIONAL | Observational Model: |Time Perspective: p | 2010-02-01 | 2023-04-13 | 2023-04-13 | 2024-09-05 | null | 2024-09-05 | null | null |
NCT06585176 | Epidemiological Studies and Risk Factor Analysis of GERD in Xiamen City | https://clinicaltrials.gov/study/NCT06585176 | null | RECRUITING | Gastroesophageal Reflux Disease (GERD) is a condition characterized by the reflux of gastric and duodenal contents into the esophagus, primarily manifested by symptoms such as acid regurgitation and heartburn. GERD significantly affects patients' daily lives and health-related quality of life. Prolonged gastroesophagea... | NO | Gastroesophageal Reflux Disease|Epidemiology|Risk Factors | null | The prevalence of GERD in Xiamen city, Gastroesophageal reflux disease (GERD) is the most prevalent gastrointestinal disorder in the world. In this study, we will study the incidence of GERD in Xiamen city., 3 months.|The percentage of reflux esophagitis, The percentage of participants diagnosed with reflux esophagitis... | The life quality of GERD patients who were diagnosed by endoscopy, The life quality of GERD patients with different main symptoms before PPI test will be measured via the 50-item short form health survey , in which higher scores mean a better quality of life., 3 months.|The sensitivity of GERD-Q for diagnosis of GERD, ... | null | Zhongshan Hospital (Xiamen), Fudan University | null | ALL | CHILD, ADULT, OLDER_ADULT | null | 1,600 | OTHER | OBSERVATIONAL | Observational Model: |Time Perspective: p | 2024-08-01 | 2025-08-30 | 2026-11-30 | 2024-09-05 | null | 2024-09-05 | null | null |
NCT06585163 | Study to Investigate the Safety, Tolerability and Pharmacokinetics of QEV-817 Oral Suspension | https://clinicaltrials.gov/study/NCT06585163 | null | NOT_YET_RECRUITING | This study has been designed to assess the safety, tolerability, and pharmacokinetics of a therapeutic dose of hydrocodone bitartrate with and without an oral dose of doxapram hydrochloride in healthy volunteers who are naltrexone-blocked. | NO | Healthy | DRUG: Hydrocodone Bitartrate|DRUG: Doxapram Hydrochloride | Number of Participants with Treatment-Emergent Adverse Events (TEAEs), Incidence, nature, and severity of TEAEs, Day 1 to Day 5|Number of Participants with Abnormal Laboratory Assessments, 12-Lead Electrocardiogram (ECG), and Vital Signs, Changes from baseline in physical examination, vital signs, 12-lead ECG assessmen... | Plasma PK Parameters (Cmax), Maximal plasma concentrations for hydrocodone and doxapram, Day 2 and Day 4|Plasma PK Parameters (AUC0-inf), Plasma area under the curve for hydrocodone and doxapram, Day 2 and Day 4|Plasma PK Parameters (Tmax), Time to maximal plasma concentrations for hydrocodone and doxapram, Day 2 and D... | null | Quivive Pharma, Inc. | National Institute on Drug Abuse (NIDA) | ALL | ADULT | null | 8 | INDUSTRY | INTERVENTIONAL | Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: SUPPORTIVE_CARE | 2024-09 | 2024-12 | 2024-12 | 2024-09-05 | null | 2024-09-05 | Cleveland Clinic Main Campus, Cleveland, Ohio, 44195, United States | null |
NCT06585150 | Study of Obeldesivir to Treat Nonhospitalized Adults With Acute Respiratory Syncytial Virus (RSV) Infection | https://clinicaltrials.gov/study/NCT06585150 | null | NOT_YET_RECRUITING | The goal of this clinical study is to learn more about the study drug, obeldesivir (ODV; GS-5245), and how safe and effective it is in treating nonhospitalized adults with acute respiratory syncytial virus (RSV) infection. The researchers want to see if obeldesivir can help participants' symptoms get better faster.
Th... | NO | RSV Infection | DRUG: Obeldesivir|DRUG: Obeldesivir Placebo | Time to Alleviation of Targeted Respiratory Syncytial Virus (RSV) Symptoms as Measured by Respiratory Infection Intensity and Impact Questionnaire (RiiQ) through Day 15, The RiiQ symptom scale is a 13-item questionnaire rated on a 4-point scale. Each symptom is rated on a scale of 0 to 3 where 0=None, 1=Mild, 2=Moderat... | Time to Sustained Alleviation of Targeted RSV Symptoms as Measured by RiiQ Through Day 15, The RiiQ symptom scale is a 13-item questionnaire rated on a 4-point scale. Each symptom is rated on a scale of 0 to 3 where 0=None, 1=Mild, 2=Moderate, and 3=Severe. Higher scores indicated greater severity., Day 1 up to Day 15|... | null | Gilead Sciences | null | ALL | ADULT, OLDER_ADULT | null | 240 | INDUSTRY | INTERVENTIONAL | Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT | 2024-09 | 2025-09 | 2025-09 | 2024-09-05 | null | 2024-09-05 | null | null |
NCT06585137 | Impact of a Web-Based Mind-Body Awareness Program on Women Undergoing Infertility Treatment | https://clinicaltrials.gov/study/NCT06585137 | null | NOT_YET_RECRUITING | The goal of this two-group parallel randomized controlled study is to determine the effect of a web-based mind-body-based awareness program based on Meleis Transition Theory on fertility awareness and readiness levels in women receiving infertility treatment. | NO | Infertility, Female | null | Fertility Awareness Scale, This scale was developed to measure fertility awareness in women. The scale is Likert-type and has 19 items and two sub-dimensions (Body Awareness, Cognitive Awareness). Items in the scale are scored from 1 to 5 (1-Never, 2-Rarely, 3-Occasionally, 4-Most of the time and 5-Always) and there ar... | Introductory Information Form, Follicle-stimulating hormone (FSH) and estradiol (E2) levels, number of oocytes collected, embryo transfer status, and blood pregnancy test results will be taken from the patient file and added to the form., FSH and E2 levels will be monitored on the 2nd-3rd day of the menstrual cycle, th... | null | Hacettepe University | null | FEMALE | ADULT | null | 78 | OTHER | INTERVENTIONAL | Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE | 2025-07-01 | 2026-07-01 | 2027-07-01 | 2024-09-05 | null | 2024-09-05 | null | null |
NCT06585124 | Flow Cytometry for the Study of T-Cell Populations in Hemophagocytic Lymphohistiocytosis Associated With Lymphomas | https://clinicaltrials.gov/study/NCT06585124 | LA-HLH | RECRUITING | The goal of this study is to explore the associations between T cell activation and the occurrence of hemophagocytic lymphohistiocytosis (HLH) in patients with newly diagnosed lymphomas. The specific aims are:
Prediction of Lymphoma-Associated HLH (LA-HLH): Compare flow cytometric T cell activation markers with the H-... | NO | Lymphoma|Hemophagocytic Lymphohistiocytoses | DIAGNOSTIC_TEST: Flow Cytometry | Assocation of flow cytometry parameters on peripheral blood with the H-score, the standard for the diagnosis of lymphoma-associated HLH, Diagnostic rate of flow cytometry for lymphoma-associated HLH, 2 years | Determine the incidence of LA-HLH, incidence rate, 2 years|To evaluate the outcome of patients with LA-HLH, overall survival, 2 years|Define the rate of complete responses to lymphoma treatment, Complete remission rate, 2 years | null | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | null | ALL | ADULT, OLDER_ADULT | null | 150 | OTHER | OBSERVATIONAL | Observational Model: |Time Perspective: p | 2024-05-01 | 2025-05-01 | 2026-05-01 | 2024-09-05 | null | 2024-09-05 | Stefan Hohaus, Rome, Lazio, 00168, Italy | null |
NCT06585111 | Effect of Individual Counseling Interventions Based On Health Action Process Approach Model On Breastfeeding Duration | https://clinicaltrials.gov/study/NCT06585111 | null | COMPLETED | The aim of this prospective, randomized controlled experimental clinical trial was to examine the effect of individual counseling interventions based on the Health Action Process Approach Model on breastfeeding duration in twin pregnancies. Women in the intervention group received breastfeeding education using motivati... | NO | Breast Feeding | OTHER: Intervention | Breastfeeding duration of twin babies until the sixth month postpartum after counseling, The duration of breastfeeding the twins was measured using a breastfeeding follow-up form after the counseling intervention using motivational interviewing techniques. The breastfeeding follow-up form included questions about the n... | Duration of exclusive breastfeeding of twin babies after consultation until the sixth month after birth, The duration of breastfeeding the twins was measured using a breastfeeding follow-up form after the counseling intervention using motivational interviewing techniques. The breastfeeding follow-up form included quest... | null | Ege University | null | FEMALE | ADULT, OLDER_ADULT | null | 68 | OTHER | INTERVENTIONAL | Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE | 2022-09-15 | 2023-09-15 | 2023-09-15 | 2024-09-05 | null | 2024-09-05 | Ege University, İzmir, Bornova, 35030, Turkey | null |
NCT06585098 | The Effect of Game-Based Virtual Reality Application on the Development of Postoperative Care Skills of Nursing Students for Hysterectomy | https://clinicaltrials.gov/study/NCT06585098 | null | COMPLETED | This study aimed to determine the effect of game-based virtual reality application on nursing students' self-confidence in postoperative care knowledge, skills, satisfaction and learning following hysterectomy surgery. | NO | Nursing|Hysterectomy|Game-Based Learning | OTHER: game based learning | Satisfaction with Educational Methods Survey, This is a survey developed by Gürpınar and also used in his research. This survey consists of 16 statements. One of these statements is the statement that asks whether or not the student is satisfied with the education by saying "I am generally satisfied with this education... | null | null | Ege University | The Scientific and Technological Research Council of Turkey | ALL | CHILD, ADULT, OLDER_ADULT | null | 84 | OTHER | INTERVENTIONAL | Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: OTHER | 2023-03-15 | 2024-03-15 | 2024-07-17 | 2024-09-05 | null | 2024-09-05 | Ege Üniversitesi Kadın Sağlığı Ve Hemşireliği, İzmir, Eyalet/Yerleşke, 1, Turkey | null |
NCT06585085 | Physical Activity and Sedentary Behavior During Pregnancy | https://clinicaltrials.gov/study/NCT06585085 | PREGMOUV | NOT_YET_RECRUITING | Our main objective is to evaluate the intervention that best enables women's adherence to physical activity (PA).
Our hypothesis is that identifying types of interventions suitable for pregnant women (in-person PA sessions, videoconferences or mixed format) could help improve their PA level and simultaneously reduce t... | NO | Pregnant Woman | BEHAVIORAL: In person PA sessions|BEHAVIORAL: Interactive videoconference PA sessions|BEHAVIORAL: In person and by videoconference (mixed format) PA sessions. | Women's adherence to PA at the end of the second trimester, measurement of the PA level, measured by accelerometer, expressed in MET.minutes/week by wearing a tri-axial accelerometer on the hip, between 24 and 30 weeks of gestation | women's adherence in terms of reduction of Sedentary Behaviors at the end of the 2nd trimester, measurement of sedentary time (defined as a state of wakefulness characterized by an energy expenditure less than or equal to 1.5 METs) between getting up and going to bed using a tri-axial hip accelerometer, between 24 and ... | null | University Hospital, Clermont-Ferrand | Réseau de Santé en Périnatalité d'Auvergne|ASM Omnisports - Pôle Sport-Santé|Office Municipal du Sport - Espace Sport Santé|Observatoire national de l'activité physique et de la sédentarité|Ville de Clermont-Ferrand|Ministère de la Santé et de la Prévention | FEMALE | ADULT, OLDER_ADULT | null | 630 | OTHER | INTERVENTIONAL | Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH | 2024-09 | 2027-10 | 2027-10 | 2024-09-05 | null | 2024-09-05 | CHU de Clermont-Ferrand, Clermont-Ferrand, 63000, France | null |
NCT06585072 | Pancreatic Cancer and Diabetes Mellitus | https://clinicaltrials.gov/study/NCT06585072 | null | NOT_YET_RECRUITING | The goal of this observational study is to learn about post-surgery of pancreatic cancer diabetes mellitus.The main questions it aims to answer are:
1. Are the incident rates of glucose metabolic disorders (pre-diabetes and diabetes mellitus) after pancreatic cancer of different etiologies the same?
2. Are alterations... | NO | Pancreatic Cancer|Surgery|Diabetes Mellitus | null | Number of Participants Who developed glucose metabolic disorders(pre-diabetes and diabetes mellitus), The diagnosis of glucose disorders should be made applying criteria of the American Diabetes Association., From enrollment to five years after the end of the surgery | Overall Survival, From enrollment to five years after the end of the surgery|Disease-Free Survival, From enrollment to five years after the end of the surgery | null | Shanghai Changzheng Hospital | null | ALL | ADULT, OLDER_ADULT | null | 150 | OTHER | OBSERVATIONAL | Observational Model: |Time Perspective: p | 2024-09-03 | 2026-09-01 | 2026-09-01 | 2024-09-05 | null | 2024-09-05 | null | null |
NCT06585059 | Clinical Trial of TQB2928 in Combination With a Third-Generation Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) in Patients With Advanced Non-Small Cell Lung Cancers | https://clinicaltrials.gov/study/NCT06585059 | null | NOT_YET_RECRUITING | This is a Phase Ib study to evaluate the safety, tolerability, and efficacy of TQB2928 in combination with third-generation EGFR TKIs in subjects with advanced non-small cell lung cancer, and to determine the recommended Phase II dose (RP2CD). | NO | Advanced Non-small Cell Lung Cancer | DRUG: TQB2928 injection + Almonertinib Mesilate Tablets | Phase II recommended combination doses (RP2CD), The recommended dosage for drug combination therapy in the second phase of clinical trials (i.e. Phase II clinical trials)., Baseline up to 24 months|Objective Response Rate (ORR), Defined as the percentage of Complete Response (CR) plus partial response (PR) assessed by ... | Elimination half-life (t1/2), The time required for plasma drug concentration to decrease by half., Cycle 1 Day1: in 0.5 hour pre-dose and immediately after dose, 2, 6, 24 hours; Day1 and Day15 of Cycle 1, Cycle 2 Day1: in 0.5 hour pre-dose and immediately after dose; Day1 on Cycle 3, Cycle 4, Cycle 5: in 0.5 hour pre-... | null | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | null | ALL | ADULT, OLDER_ADULT | null | 20 | INDUSTRY | INTERVENTIONAL | Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT | 2024-09 | 2025-12 | 2026-12 | 2024-09-05 | null | 2024-09-05 | Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, China | null |
NCT06585046 | The Risk Factors and Its Prognosis of Hyperglycemia Secondary to Pancreatic Surgery | https://clinicaltrials.gov/study/NCT06585046 | null | COMPLETED | The goal of this observational study is to learn about post-pancreatic surgery diabetes mellitus(PCRD).The main questions it aims to answer are:
1. What are the clinical characteristics of PCRD?
2. What are the related factors for PCRD? All patients with pancreatic surgery have been given standardized treatment fot th... | NO | Pancreatic Surgey|Diabetes Mellitus | null | Incidence of glycaemic disorders（prevalence of diabetes） (postoperative fasting blood glucose/HbA1C), The main objective of this study was the incidence of glucose metabolism disorders in patients treated with pancreatic surgery in our centre., (within 5 years after surgery) | overall survival, within 5 years after surgery|Disease-Free Survival, within 5 years after surgery | null | Shanghai Changzheng Hospital | null | ALL | ADULT, OLDER_ADULT | null | 382 | OTHER | OBSERVATIONAL | Observational Model: |Time Perspective: p | 2017-01-01 | 2024-08-01 | 2024-08-01 | 2024-09-05 | null | 2024-09-05 | null | null |
NCT06585033 | Placebo Effect in Spinal Cord Electrical Stimulation for Pain | https://clinicaltrials.gov/study/NCT06585033 | PISCES | NOT_YET_RECRUITING | Objective: To evaluate if spinal cord stimulation (SCS) performs better than placebo (no stimulation) in the long term to reduce persistent neuropathic leg pain refractory to medication and other conservative treatments in patients who have undergone lumbar spinal surgery.
Study design: Multicenter, double blind, rand... | NO | Chronic Postoperative Pain | null | Comparison between active subthreshold spinal cord stimulation and sham stimulation in reducing neuropathic leg pain, The difference in change in neuropathic leg pain intensity scores measured by the numeric rating scale (NRS) questionnaire between a 3-month period with subthreshold stimulation and a 3-month period wit... | Comparison between active subthreshold spinal cord stimulation and sham stimulation, Physical functioning measured using the Oswestry Disability Index (ODI) questionnaire, Baseline and 3, 6 and 12 months|Comparison between active subthreshold spinal cord stimulation and sham stimulation, • Quality of life measured usin... | null | Sahlgrenska University Hospital, Sweden | null | ALL | ADULT, OLDER_ADULT | null | 50 | OTHER | INTERVENTIONAL | Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT | 2024-09-15 | 2026-08-31 | 2026-08-31 | 2024-09-05 | null | 2024-09-05 | null | null |
NCT06585020 | Amikacin Liposome Inhalation Suspension for Treatment of Mycobacterium Xenopi Pulmonary Infection | https://clinicaltrials.gov/study/NCT06585020 | AKAPI | NOT_YET_RECRUITING | Treatment of Mycobacterium xenopi (MX) lung disease is not-well- tolerated and concerned a growing number of patients, especially with chronic pulmonary diseases or immunosuppression. The outcome of these patients is poor, and treatment is very long. Indeed, this duration is based on the date of sputum conversion. Trea... | NO | Mycobacterium; Xenopi|Lung Diseases | null | variation of sputum conversion rate in ARIKAYCE® addition group compared to standard treatment, 3 months | variation of time to culture conversion between both groups, at 3 month|variation of mortality between both groups, at 12 months|variation of mortality between both groups, at 24 months | null | Centre Hospitalier Universitaire, Amiens | null | ALL | ADULT, OLDER_ADULT | null | 190 | OTHER | INTERVENTIONAL | Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT | 2024-10 | 2026-08 | 2027-08 | 2024-09-05 | null | 2024-09-05 | null | null |
NCT06585007 | Metastasis-directed Therapy in Oligoprogressive Castration-refractory Prostate Cancer | https://clinicaltrials.gov/study/NCT06585007 | MEDCARE | RECRUITING | Evaluation of the impact of metastasis-directed therapy in patients with castration-refractory prostate cancer and a maximum of 5 progressive lesions. | NO | Castration-resistant Prostate Cancer|Oligoprogressive | RADIATION: Radiotherapy|PROCEDURE: metastasectomy | Overall Survival, Overall Survival, will be calculated from the day of randomisation until death from any cause, wichever came first, assessed up to 5 years. | Quality of life scoring EORTC QLQ-C30, Quality of life scoring using the EORTC QLQ-C30, Assessments are planned at baseline and during follow-up consultation at month 1, month 3, month 6, month 12 and month 24|Quality of life scoring EORTC QLQ-PR25, Quality of life scoring using the EORTC QLQ-PR25, Assessments are plan... | null | Universitaire Ziekenhuizen KU Leuven | null | MALE | ADULT, OLDER_ADULT | null | 246 | OTHER | INTERVENTIONAL | Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT | 2023-12-19 | 2029-01-20 | 2029-01-20 | 2024-09-05 | null | 2024-09-05 | University Hospitals Leuven, Leuven, Belgium | null |
NCT06584994 | Investigating the Role of Genetics in Disease Predisposition | https://clinicaltrials.gov/study/NCT06584994 | null | ENROLLING_BY_INVITATION | Gametogenesis is the production of sperm and eggs; it takes place through the process of meiosis. Gametogenesis is subject to the acquisition of mutations as with other processes in the body. Many of these mutations are somatic, meaning that they occur during life as part of the process of cell division rather than bei... | NO | Predisposition, Genetic|Cancer|Mutation|Fertility Disorders | null | How often mutations accumulate in healthy reproductive tissues, Establish how often mutations (changes in DNA) accumulate in healthy reproductive tissues (testes and ovaries)., 7 years | Identification and Characterisation of Mutations, Determine the genetic changes in gonadal tissues, including the frequency, type, and nature of mutations acquired during germ cell production, and identify the genes and cellular processes that these mutations may alter., 7 years|Comparative Analysis of Mutation Rates, ... | null | The Wellcome Sanger Institute | null | ALL | CHILD, ADULT, OLDER_ADULT | null | 1,000 | OTHER | OBSERVATIONAL | Observational Model: |Time Perspective: p | 2021-06-20 | 2027-03-01 | 2027-03-01 | 2024-09-05 | null | 2024-09-05 | null | null |
End of preview.
README.md exists but content is empty.
- Downloads last month
- 11